Peter MacCallum Cancer Centre and Affymetrix Initiate Five-Year Translational Research Collaboration
September 27 2006 - 8:00AM
Business Wire
Affymetrix Inc. (Nasdaq:AFFX) announced today that it has entered
into a five-year collaboration with the Peter MacCallum Cancer
Centre (Peter Mac) in Melbourne, Australia, to analyze genomic
information across large patient samples. Under terms of the
agreement, Peter Mac researchers will use Affymetrix GeneChip�
microarray technology for translational research projects,
beginning with studies on ovarian cancer and carcinoma of unknown
primaries. Peter Mac researchers will use Affymetrix GeneChip
technology to perform large-scale clinical studies. The Affymetrix
technology will enable them to more rapidly discover RNA and DNA
patterns that can better classify, manage and treat complex
diseases. �We are excited about the opportunities created by the
Translational Medicine Program, particularly the chance to apply
new technologies to help us answer important clinical questions,�
said Professor David Bowtell, Ph.D., director of research at the
Peter MacCallum Cancer Centre. �We are keen to help our
collaborators across Australia gain access to Affymetrix
technology, as we continue to develop as a major center for cancer
genomics and genetics. We also see the program providing
opportunities to interact with other centers worldwide that are
involved in translational research.� To watch the full Affymetrix
UserForum interview with Professor Bowtell, please visit:
http://www.affymetrix.com/userForum/news/collaborations/bowtell.uf
�Affymetrix is excited to be working with a leading research
organization such as the Peter MacCallum Cancer Centre to help
bring more effective personalized tests and therapies to market
faster,� said Robert Wells, vice president, International Markets
Group and Corporate Affairs at Affymetrix. �Together, we hope to
accelerate clinical research, improve patient care, and open the
door to new genomic applications.� Affymetrix collaborates with
academic institutions, advocacy groups and the pharmaceutical
and�diagnostics�community through its
Translational�Medicine�Program to develop�molecular signatures for
improving patient care. Affymetrix GeneChip microarray technology
helps researchers to diagnose and�tailor treatments for individual
patients�by identifying and measuring the genetic information
associated with complex diseases.
The�Translational�Medicine�Program complements the Powered by
Affymetrix� program, which enables companies to license GeneChip
technology to create innovative, custom-designed microarray
products based on signatures such as those of our translational
medicine partners. This technology is already being used in many
applications, including diagnostics, forensics, animal, industrial
and food testing. Millennium Science Pty. Ltd. will supply the
Affymetrix microarray technology and provide technical support to
the Peter Mac Cancer Centre. Since being founded in 1999,
Millennium Science has grown into a leading distributor of
instrumentation and reagents for the biotechnology research and
industrial markets across Australia and New Zealand. About Peter
MacCallum Cancer Centre As Australia�s foremost cancer centre,
Peter Mac provides quality treatment and support to patients and
their families. Underpinned by research and the best evidence
available, Peter Mac broadly influences cancer care in the
community through multi-disciplinary partnerships, research and
education. The Research Division is located at Peter Mac, East
Melbourne. Peter Mac Research employs nearly 300 staff, making it
not only Australia's largest, but also one of the world's largest
groups dedicated to cancer research. Research in the Division is
undertaken within the broad framework of research programs in
Cellular & Molecular Biology, Cancer Immunology and Cancer
Genomics & Genetics. The latter program is home to several
large collaborative cancer studies, including kConFab, which
focuses on familial breast cancer, and the Australian Ovarian
Cancer Study. About Affymetrix Affymetrix scientists invented the
world's first high-density microarray in 1989 and began selling the
first commercial microarray in 1994. Since then, Affymetrix
GeneChip� technology has become the industry standard in molecular
biology research. Affymetrix technology is used by the world's top
pharmaceutical, diagnostic and biotechnology companies as well as
leading academic, government and not-for-profit research
institutes. More than 1,400 systems have been installed around the
world and more than 7,000 peer-reviewed papers have been published
using the technology. Affymetrix' patented photolithographic
manufacturing process provides the most information capacity
available today on an array, enabling researchers to use a
whole-genome approach to analyzing the relationship between
genetics and health. Affymetrix is headquartered in Santa Clara,
Calif., with manufacturing facilities in Sacramento, Calif., and
Bedford, Mass. The company maintains important sales and marketing
operations in Europe and Asia and has about 1,100 employees
worldwide. For more information about Affymetrix, please visit the
company's website at www.affymetrix.com. All statements in this
press release that are not historical are "forward-looking
statements" within the meaning of Section 21E of the Securities
Exchange Act as amended, including statements regarding Affymetrix'
"expectations," "beliefs," "hopes," "intentions," "strategies," or
the like. Such statements are subject to risks and uncertainties
that could cause actual results to differ materially for Affymetrix
from those projected, including, but not limited to: risks and
uncertainties associated with the outcome of the collaboration with
the Peter MacCallum Cancer Centre discussed in this press release;
risks of the Company's ability to achieve and sustain higher levels
of revenue, higher gross margins, reduced operating expenses;
uncertainties relating to technological approaches, manufacturing,
product development; personnel retention; uncertainties related to
cost and pricing of Affymetrix products; dependence on
collaborative partners; uncertainties relating to sole source
suppliers; uncertainties relating to FDA and other regulatory
approvals; competition; risks relating to intellectual property of
others and the uncertainties of patent protection and litigation.
These and other risk factors are discussed in Affymetrix' Form
10-K/A for the year ended December 31, 2005, and other SEC reports,
including its Quarterly Reports on Form 10-Q for subsequent
quarterly periods. Affymetrix expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in Affymetrix' expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based. NOTE: Affymetrix, the Affymetrix logo, and GeneChip are
registered trademarks owned or used by Affymetrix Inc. Affymetrix
Inc. (Nasdaq:AFFX) announced today that it has entered into a
five-year collaboration with the Peter MacCallum Cancer Centre
(Peter Mac) in Melbourne, Australia, to analyze genomic information
across large patient samples. Under terms of the agreement, Peter
Mac researchers will use Affymetrix GeneChip(R) microarray
technology for translational research projects, beginning with
studies on ovarian cancer and carcinoma of unknown primaries. Peter
Mac researchers will use Affymetrix GeneChip technology to perform
large-scale clinical studies. The Affymetrix technology will enable
them to more rapidly discover RNA and DNA patterns that can better
classify, manage and treat complex diseases. "We are excited about
the opportunities created by the Translational Medicine Program,
particularly the chance to apply new technologies to help us answer
important clinical questions," said Professor David Bowtell, Ph.D.,
director of research at the Peter MacCallum Cancer Centre. "We are
keen to help our collaborators across Australia gain access to
Affymetrix technology, as we continue to develop as a major center
for cancer genomics and genetics. We also see the program providing
opportunities to interact with other centers worldwide that are
involved in translational research." To watch the full Affymetrix
UserForum interview with Professor Bowtell, please visit:
http://www.affymetrix.com/userForum/news/collaborations/bowtell.uf
"Affymetrix is excited to be working with a leading research
organization such as the Peter MacCallum Cancer Centre to help
bring more effective personalized tests and therapies to market
faster," said Robert Wells, vice president, International Markets
Group and Corporate Affairs at Affymetrix. "Together, we hope to
accelerate clinical research, improve patient care, and open the
door to new genomic applications." Affymetrix collaborates with
academic institutions, advocacy groups and the pharmaceutical and
diagnostics community through its Translational Medicine Program to
develop molecular signatures for improving patient care. Affymetrix
GeneChip microarray technology helps researchers to diagnose and
tailor treatments for individual patients by identifying and
measuring the genetic information associated with complex diseases.
The Translational Medicine Program complements the Powered by
Affymetrix(TM) program, which enables companies to license GeneChip
technology to create innovative, custom-designed microarray
products based on signatures such as those of our translational
medicine partners. This technology is already being used in many
applications, including diagnostics, forensics, animal, industrial
and food testing. Millennium Science Pty. Ltd. will supply the
Affymetrix microarray technology and provide technical support to
the Peter Mac Cancer Centre. Since being founded in 1999,
Millennium Science has grown into a leading distributor of
instrumentation and reagents for the biotechnology research and
industrial markets across Australia and New Zealand. About Peter
MacCallum Cancer Centre As Australia's foremost cancer centre,
Peter Mac provides quality treatment and support to patients and
their families. Underpinned by research and the best evidence
available, Peter Mac broadly influences cancer care in the
community through multi-disciplinary partnerships, research and
education. The Research Division is located at Peter Mac, East
Melbourne. Peter Mac Research employs nearly 300 staff, making it
not only Australia's largest, but also one of the world's largest
groups dedicated to cancer research. Research in the Division is
undertaken within the broad framework of research programs in
Cellular & Molecular Biology, Cancer Immunology and Cancer
Genomics & Genetics. The latter program is home to several
large collaborative cancer studies, including kConFab, which
focuses on familial breast cancer, and the Australian Ovarian
Cancer Study. About Affymetrix Affymetrix scientists invented the
world's first high-density microarray in 1989 and began selling the
first commercial microarray in 1994. Since then, Affymetrix
GeneChip(R) technology has become the industry standard in
molecular biology research. Affymetrix technology is used by the
world's top pharmaceutical, diagnostic and biotechnology companies
as well as leading academic, government and not-for-profit research
institutes. More than 1,400 systems have been installed around the
world and more than 7,000 peer-reviewed papers have been published
using the technology. Affymetrix' patented photolithographic
manufacturing process provides the most information capacity
available today on an array, enabling researchers to use a
whole-genome approach to analyzing the relationship between
genetics and health. Affymetrix is headquartered in Santa Clara,
Calif., with manufacturing facilities in Sacramento, Calif., and
Bedford, Mass. The company maintains important sales and marketing
operations in Europe and Asia and has about 1,100 employees
worldwide. For more information about Affymetrix, please visit the
company's website at www.affymetrix.com. All statements in this
press release that are not historical are "forward-looking
statements" within the meaning of Section 21E of the Securities
Exchange Act as amended, including statements regarding Affymetrix'
"expectations," "beliefs," "hopes," "intentions," "strategies," or
the like. Such statements are subject to risks and uncertainties
that could cause actual results to differ materially for Affymetrix
from those projected, including, but not limited to: risks and
uncertainties associated with the outcome of the collaboration with
the Peter MacCallum Cancer Centre discussed in this press release;
risks of the Company's ability to achieve and sustain higher levels
of revenue, higher gross margins, reduced operating expenses;
uncertainties relating to technological approaches, manufacturing,
product development; personnel retention; uncertainties related to
cost and pricing of Affymetrix products; dependence on
collaborative partners; uncertainties relating to sole source
suppliers; uncertainties relating to FDA and other regulatory
approvals; competition; risks relating to intellectual property of
others and the uncertainties of patent protection and litigation.
These and other risk factors are discussed in Affymetrix' Form
10-K/A for the year ended December 31, 2005, and other SEC reports,
including its Quarterly Reports on Form 10-Q for subsequent
quarterly periods. Affymetrix expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in Affymetrix' expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based. NOTE: Affymetrix, the Affymetrix logo, and GeneChip are
registered trademarks owned or used by Affymetrix Inc.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024